Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 14NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Leukemia 19Lymphoma 15Burkitt Lymphoma 8Neoplasms, Plasma Cell 5Hodgkin Disease 5Recurrence 4Leukemia, Biphenotypic, Acute 4Immunoglobulin Light-chain Amyloidosis 4Waldenstrom Macroglobulinemia 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Vomiting 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Disease 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Smoldering Multiple Myeloma 1Seminoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Myelography 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Smoldering Multiple Myeloma × Dexamethasone × Clear all
NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡